OncoMatch/Clinical Trials/NCT05432518

Pilot Trial for Treatment of Recurrent Glioblastoma

Is NCT05432518 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments for glioblastoma.

Early Phase 1RecruitingAHS Cancer Control AlbertaNCT05432518Data as of May 2026

Treatment: Afatinib · Dasatinib · Palbociclib · Everolimus · Olaparib — This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Biomarker criteria

Required: IDH1 wild-type

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: radiation therapy — initial

after initial treatment with radiation therapy and temozolomide

Must have received: alkylating agent (temozolomide) — initial

after initial treatment with radiation therapy and temozolomide

Cannot have received: investigational agent

Exception: if received within 4 weeks from the date of signing the informed consent form

has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks from the date of signing the informed consent form

Lab requirements

Blood counts

Hemoglobin <10, Neutrophils <1.5, Platelets <75 (grade ≥2 CTCAE v5.0) excluded

Kidney function

eGFR <60 (grade ≥2 CTCAE v5.0) excluded

Liver function

ALT/AST >3x ULN, Bilirubin >1.5 x ULN (grade ≥2 CTCAE v5.0) excluded

Cardiac function

history of abnormal left ventricular ejection fraction (LVEF≤ 45%) excluded; significantly abnormal ECG (baseline QTcF interval > 450 msec) excluded

Abnormal (grade ≥2 CTCAE, version 5.0) laboratory values for hematology, renal, and liver function including: Hemoglobin <10, Neutrophils <1.5, Platelets <75, ALT/AST >3x ULN, Bilirubin >1.5 x ULN, eGFR <60; history of abnormal left ventricular ejection fraction (LVEF≤ 45%); significantly abnormal ECG (baseline QTcF interval > 450 msec)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify